Sign In
Buy NSPR
$0.701
-0.0151 (-2.11%)
At Close: Jun 23, 2026
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
01:46pm, Tuesday, 16'th Jun 2026
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 12'th Jun 2026
MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, to
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
08:00am, Thursday, 11'th Jun 2026
MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
09:20pm, Wednesday, 13'th May 2026
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
04:05pm, Wednesday, 06'th May 2026
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
06:50pm, Monday, 04'th May 2026
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
06:43pm, Monday, 04'th May 2026
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
InspireMD Reports First Quarter 2026 Financial Results
04:05pm, Monday, 04'th May 2026
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro pr
MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
04:05pm, Friday, 01'st May 2026
- Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% -
InspireMD to Announce First Quarter 2026 Financial Results
04:05pm, Monday, 27'th Apr 2026
MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fi
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR)
09:20am, Tuesday, 14'th Apr 2026
NEW YORK, April 14, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating InspireMD, Inc. (NASDAQ: NSPR) on behalf of the company's shareholders. The investigation seeks to
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)
10:36am, Wednesday, 08'th Apr 2026
InspireMD (NSPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
InspireMD (NYSE:NSPR) Trading Down 6.7% – What’s Next?
02:40am, Wednesday, 08'th Apr 2026
InspireMD, Inc. (NYSE: NSPR - Get Free Report) was down 6.7% on Tuesday. The stock traded as low as $1.38 and last traded at $1.39. Approximately 15,207 shares were traded during trading, a decline of
